If You Invested in Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO) is a global healthcare company in the pharmaceutical preparation manufacturing industry. According to its SEC filings, Novo Nordisk was founded in 1923 and is headquartered in Denmark. The company’s stated purpose is to drive change to defeat serious chronic diseases, building on a long heritage in diabetes care. It focuses on pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs tens of thousands of people in many countries and markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen (Novo-B), and its American Depositary Receipts (ADRs) trade on the New York Stock Exchange under the ticker NVO.

Novo Nordisk operates primarily in diabetes and obesity care and rare disease therapies. Company reports describe a portfolio that includes GLP‑1 (glucagon-like peptide‑1) based treatments and other protein and peptide therapies targeting chronic conditions. In its financial report for the first nine months of 2025, Novo Nordisk highlighted sales growth in diabetes and obesity care as well as in rare diseases. Within diabetes and obesity care, growth was driven by GLP‑1 medicines, while the rare disease segment includes therapies for hemophilia and other serious disorders, as reflected in the company’s references to rare blood and endocrine disorders.

Business focus and therapeutic areas

Across its public communications, Novo Nordisk emphasizes four broad therapeutic and strategic pillars:

• Diabetes care – The company describes more than 100 years of heritage in developing medicines that help people with diabetes live longer, healthier lives. Its GLP‑1 diabetes portfolio is a core contributor to sales, according to the 2025 financial report.
• Obesity and weight management – Novo Nordisk presents obesity as a serious, chronic, progressive, and complex disease that requires long-term management. It has developed semaglutide‑based GLP‑1 therapies for weight management and related cardiometabolic conditions, and reports strong growth in its obesity care business.
• Rare blood and endocrine disorders – Company descriptions and pipeline updates reference rare blood disorders and rare endocrine conditions as key focus areas within its rare disease segment.
• Cardiovascular and liver-related diseases – Novo Nordisk has expanded indications for certain GLP‑1 therapies into cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis (MASH), reflecting a broader cardiometabolic and liver disease strategy.

Wegovy® and GLP‑1–based therapies

A significant part of Novo Nordisk’s recent activity centers on Wegovy® (semaglutide), a GLP‑1 receptor agonist. Company press releases and SEC filings describe Wegovy® in multiple formulations and indications:

• Wegovy® injection 2.4 mg – An injectable prescription medicine used with a reduced calorie diet and increased physical activity to help adults and certain adolescents with obesity, or some adults with overweight and weight‑related medical problems, lose weight and keep it off. It is also indicated to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. Wegovy® injection has additionally been approved in the US to treat adults with MASH with moderate to advanced liver fibrosis (but not cirrhosis) in conjunction with lifestyle measures.
• Wegovy® pill (oral semaglutide 25 mg) – A once‑daily oral GLP‑1 therapy approved by the US FDA to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and at least one weight‑related medical condition. In the OASIS 4 trial, oral semaglutide 25 mg demonstrated a mean weight loss of 16.6% when treatment was adhered to in adults with obesity or overweight with comorbidities. Novo Nordisk’s December 2025 Form 6‑K notes that the Wegovy® pill is the first oral GLP‑1 therapy approved for weight management.

Press releases further describe the Wegovy® pill as the first and only oral GLP‑1 medicine for obesity in the US, used together with a reduced calorie diet and increased physical activity to help adults with obesity, or adults with overweight and weight‑related medical problems, lose weight and keep it off. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Obesity, cardiometabolic and liver disease strategy

Novo Nordisk’s communications portray obesity as a major public health challenge influenced by biology, genetics, social determinants of health, and the environment. The company positions its GLP‑1 therapies as part of long‑term, medically supervised obesity care. It has also advanced semaglutide into liver disease: the ESSENCE phase 3 trial in adults with MASH and moderate to advanced liver fibrosis supported the FDA’s accelerated approval of Wegovy® for this indication, based on histological improvement in steatohepatitis and fibrosis.

The company also reports work in cardiovascular and emerging therapy areas, including clinical programs evaluating semaglutide and other molecules in chronic heart failure and cardiomyopathy, as described in its 2025 financial report. In addition, Novo Nordisk has announced investigational programs such as CagriSema, a fixed‑dose combination of cagrilintide (a long‑acting amylin analogue) and semaglutide, being studied for adults with overweight or obesity and for people with type 2 diabetes. New analyses from the REDEFINE 1 trial, presented at ObesityWeek®, indicated reductions in systolic blood pressure, inflammatory markers, and predicted atherosclerotic cardiovascular disease risk in adults with overweight or obesity.

Pipeline, acquisitions and R&D

Novo Nordisk’s 2025 financial report and subsequent 6‑K filings highlight an active research and development pipeline. The company describes progress in several areas:

• Advancing higher‑dose and oral GLP‑1 formulations for weight management.
• Submitting semaglutide 2.4 mg for MASH in the EU and Japan, and obtaining US approval for MASH with moderate to advanced fibrosis.
• Developing and submitting Mim8 for regulatory approval in the EU and US for rare blood disorders.
• Initiating phase 3 development of cagrilintide as a potential amylin monotherapy treatment for weight management.
• Agreeing to acquire Akero Therapeutics, Inc. and its phase 3 FGF21 analogue in MASH, and acquiring a clinical‑stage MASP‑3 inhibitor (zaltenibart) in rare blood disorders.
• Submitting oral semaglutide 25 mg for weight management in the US and EU, and planning further development of subcutaneous and oral amycretin for weight management.

These activities underscore Novo Nordisk’s stated aim to raise the innovation bar in diabetes treatment, develop new obesity therapies, strengthen its rare disease pipeline, and establish a presence in cardiovascular and emerging therapy areas.

Market presence and scale

In multiple filings, Novo Nordisk notes that it employs about 78,400–78,500 people in roughly 80 countries and markets its products in around 170 countries. The company reports that its diabetes value market share is slightly above 30% on a moving annual total basis, and that obesity care sales have grown rapidly, driven by Wegovy®. It also reports providing medical treatment to tens of millions of people living with diabetes and millions of people living with obesity, illustrating the scale of its global reach.

US operations and patient access initiatives

Novo Nordisk has a significant presence in the United States, where it reports decades of operations and thousands of employees across multiple manufacturing, R&D, and corporate locations. Its US communications emphasize patient access and affordability initiatives for Wegovy®:

• NovoCare® Pharmacy – A direct‑to‑patient home delivery option for cash‑paying patients prescribed Wegovy®. NovoCare® Pharmacy supports benefit verification, refill reminders, and access to live support from a case manager. It is intended to provide reliable access to authentic, FDA‑approved Wegovy® and to help patients avoid risks associated with compounded semaglutide products.
• Wegovy® savings offers – A series of offers and savings programs for self‑paying patients and those with commercial insurance that does not cover obesity medicines. These programs have included reduced monthly prices for Wegovy® and introductory offers for new patients, as detailed in several press releases.
• Telehealth and pharmacy collaborations – Collaborations with telehealth providers such as Ro, LifeMD and WeightWatchers, and with pharmacies including CenterWell Pharmacy and large retail chains, to expand access to Wegovy® while emphasizing authentic, FDA‑approved medicines.

The company has also launched public education campaigns such as “Choose the Real Thing” and “Power of Wegovy®” to raise awareness about the dangers of knockoff compounded semaglutide and to address stigma around obesity.

Regulatory and legal stance on compounded semaglutide

Several Novo Nordisk press releases describe the company’s concern about compounded or knockoff “semaglutide” products. Novo Nordisk cites FDA warnings that poor‑quality compounded drugs can be linked to serious patient illnesses and deaths, and notes that many foreign suppliers of semaglutide used in compounding have not had their manufacturing processes authorized or approved by the FDA. The company reports filing numerous lawsuits in multiple US states against entities that unlawfully market or sell knockoff drugs or make misleading claims about compounded semaglutide, and states that it will continue to work with regulators and law enforcement to protect patients.

Corporate governance and listings

Novo Nordisk’s governance structure includes a Board of Directors with shareholder‑elected and employee‑elected members. In 2025, the company convened an Extraordinary General Meeting to elect new board members following discussions with the Novo Nordisk Foundation regarding future board composition. Subsequent filings detail changes in board leadership, including the election of a new chair and vice chair and the appointment of board committee members.

The company also regularly discloses transactions in Novo Nordisk shares by board members, executives and associated persons, in line with market abuse regulations. These disclosures provide transparency on insider trading activity in Novo Nordisk B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.

Sustainability and long-term orientation

Novo Nordisk repeatedly states that it aims to conduct business in a financially, socially, and environmentally responsible way. Its strategic aspirations include progressing towards lower environmental impact, adding value to society, and maintaining long‑term, responsible business practices. The company links its long history in diabetes care to a broader purpose of defeating serious chronic diseases, including obesity, rare blood disorders, and endocrine conditions, through long‑term investment in science and access initiatives.